Future of Healthcare & Wellness: The Impact of GLP-1s on Sleep Apnea
Video • August 12, 2024
Adam Spielman, Head of Health, Citi Global Insights with Michael Farrell, CEO at ResMed and Carlos Nunez, CMO, discuss the impact of GLP-1s on Sleep Apnea companies.
Key topics:
How do sleep apnea patients who use GLP-1s behave differently from non-users?
How does this affect companies providing solutions for obstructive sleep apnea
To what extent is ResMed changing its strategy because of GLP-1s?
If GLP-1s do reduce obesity long term, what impact would there be?